Home 
Contact Medical Affairs
Blood EOS Calculator
Vaccine Stability Calculator
REPORT SUSPECTED ADVERSE REACTIONS 
Pipeline
At GSK, our pipeline is focused on unlocking the science of the immune system, human genetics, and advanced technologies to develop vaccines and specialty medicines.
Our products in development progress through three stages: phase I, phase II, and phase III/registrational. Each of these phases allows us to assess the safety and efficacy of our investigational products to eventually provide data to support applications for regulatory approval.
DISEASE STATES
Long-acting IL-5 antagonist (depemokimab)
SWIFT 1: Placebo-Controlled Efficacy and Safety Study of Depemokimab in Participants With Severe Asthma With an Eosinophilic Phenotype
SWIFT 2: A Study of Depemokimab in Participants With Severe Asthma With an Eosinophilic Phenotype
NIMBLE: A Study of Depemokimab Compared With Mepolizumab or Benralizumab in Participants With Severe Asthma With an Eosinophilic Phenotype
An Open-Label Extension Study of Depemokimab in Participants Who Were Previously Enrolled in 206713 (NCT04719832) or 213744 (NCT04718103)
IL-5 antagonist (mepolizumab)
MATINEE: Mepolizumab as Add-on Treatment IN Participants With COPD Characterized by Frequent Exacerbations and Eosinophil Level
Prospective Observational Study
Longitudinal Study for Eosinophilic Granulomatosis with Polyangiitis (Churg-Strauss)
Long-acting IL-5 antagonist (depemokimab)
OCEAN: Efficacy and Safety of Depemokimab Compared With Mepolizumab in Adults With Relapsing or Refractory EGPA
IL-5 antagonist
SPHERE: Study in Pediatrics With HypEREosinophilic Syndrome
Long-acting IL-5 antagonist (depemokimab)
DESTINY: Depemokimab in Participants With HES, Efficacy, and Safety Trial
Long-acting IL-5 antagonist (depemokimab)
ANCHOR-1: Efficacy and Safety of Depemokimab in Participants with CRSwNP
ANCHOR-2: Efficacy and Safety of Depemokimab in Participants with CRSwNP
Long-acting IL-5 antagonist (depemokimab)
A Study to Compare the Pharmacokinetics (PK) of Depemokimab When Delivered With a Safety Syringe Device (SSD) or an Autoinjector in Healthy Adult Participants
P2X3 Antagonist (camlipixant [BLU-5937])
CALM-1: A 52-Week Study of the Efficacy and Safety of BLU-5937 in Adults with Refractory Chronic Cough
P2X3 Antagonist (camlipixant [BLU-5937])
CALM-2: A 24-Week Study of the Efficacy and Safety of BLU-5937 in Adults with Refractory Chronic Cough
0 results - Use filter to search Pipeline
Disclaimer
This document contains information for healthcare providers and is intended solely for educational purposes. This display includes ongoing clinical trials for both approved and investigational compounds.
Some agents are approved in select indications. Inclusion in this display does not imply regulatory approval for these compounds or all indications. Information about all trials can be found at www.clinicaltrials.gov.
